90.9 WBUR - Boston's NPR news station
Top Stories:
PLEDGE NOW
The Mega Costs Of Miracle Drugs

Super expensive miracle drugs.  How much can we afford to pay? Plus, a look at a powerful new painkiller making headlines.

In this Saturday, Aug. 11, 2012 file photo, employees of the New Hampshire state health department set up a temporary clinic at the the middle school in Stratham, N.H., to test hundreds of people for hepatitis C related to an outbreak at nearby Exeter Hospital. A new drug, Sovaldi, is said to successful treat more than 90 percent of Hepatitis C patients. (AP)

In this Saturday, Aug. 11, 2012 file photo, employees of the New Hampshire state health department set up a temporary clinic at the the middle school in Stratham, N.H., to test hundreds of people for hepatitis C related to an outbreak at nearby Exeter Hospital. A new drug, Sovaldi, is said to successful treat more than 90 percent of Hepatitis C patients. (AP)

We all know drugs can be super-expensive in the USA, but how about this for a pharmacy bill?  The hottest new treatment for hepatitis C costs $1,000 a pill.  Eighty-four thousand dollars for a twelve-week course.  About three million Americans have hepatitis C.  Do the math.  Treat all those people and the whole system topples over.  Billions and billions.  But our system has no automatic brakes.  Americans want the best in drug therapies.  But as new drug prices climb, how far can we go?  When do we hit a wall?  Is it now?  This hour On Point:  super-expensive drugs, and the American way of health care.

– Tom Ashbrook

Guests

James Surowiecki, staff writer at the New Yorker, where he writes the financial page.

Dr. Steve Miller, chief medical officer of the pharmacy benefit management firm, Express Scripts.

Patricia Danzon, professor of health care management at the University of Pennsylvania’s Wharton School of Business.

From Tom’s Reading List

New Yorker: Biotech’s Hard Bargain — “In December the F.D.A. approved the first in a new wave of hep-C drugs, Gilead’s Sovaldi. This is huge news—not just in medicine but on Wall Street. Vamil Divan, a drug-industry analyst at Credit Suisse, told me, ‘Sovaldi and the other new hep-C drugs are great drugs for a tough disease.’ Sovaldi can cure ninety per cent of patients in three to six months, with only minor side effects. There’s just one catch: a single dose of the drug costs a thousand dollars, which means that a full, twelve-week course of treatment comes to more than eighty grand.”

NPR: Costly Hepatitis C Pill Shreds Drug Industry Sales Record — “To make the case for Sovaldi’s price, Gilead put together a chart of hepatitis C treatment costs for a variety of medicines. A combination of Sovaldi, a common form of interferon and the antiviral ribavirin, would cost $94,078 for treatment that would last 12 weeks. Other drug combinations that would take longer for treatment ranged from $64,825 to $106,673.”

New England Journal of Medicine: The Costs of Success — “Unfortunately, not all barriers to treatment will be lifted. The major limitation remaining will be economic. The current cost of a 12-week regimen of sofosbuvir alone is $84,000, or $1,000 per tablet. The addition of ledipasvir will add to the costs, and these estimates do not include expenses for diagnostic assays, monitoring, and physician visits.”

Painkiller Zohydro Sparks Addiction Concerns Anew

Lisa Girion, health and investigative reporter for the Los Angeles Times. (@lisagirion)

Boston Globe: Drugmakers dual role as friend, foe – “Doctors prescribe way too many powerful painkillers in this country. The skyrocketing overdoses are mirrored by rising prescriptions for Oxycodone, Vicodin, and other opioids, especially for middle-aged people in chronic pain. Adding another powerful painkiller to an already saturated market, especially one that is easily crushed and snorted, means more prescriptions, more abuse, and, inevitably, more deaths.”

Please follow our community rules when engaging in comment discussion on this site.
ONPOINT
TODAY
Apr 27, 2015
Flowers and ribbons adorn a tree outside the Weinstein family house in Rockville, Md. last week. Earlier, President Barack Obama ook full responsibility for the counterterror missions and offered his "grief and condolences" to the families of the hostages, Warren Weinstein of Rockville, Maryland, and Giovanni Lo Porto who were inadvertently killed by CIA drone strikes early this year. (Jose Luis Magana/AP)

American drone policy and consequences. We’ll look at secret strikes and the evolution of drone war.

Apr 27, 2015
Former Olympic athlete Bruce Jenner at a charity event in 2013. (Mark Von Holden/Invision/AP)

Bruce Jenner opens up about his gender journey. We’ll look at the big picture of transgender life in America now.

RECENT
SHOWS
Apr 24, 2015
Dick West (Dr. Walter Richard West, Wah-pah-nah-yah or Wapah Nahya, Light Foot Runner), 1912−1996, Southern Cheyenne, Oklahoma. Cheyenne Sun Dance—The Third Day, 1949. Paper, casein, 24 5/8 x 35 1/8 inches. © 2013 Philbrook Museum of Art, Inc., Museum purchase, 1949.20, Photo: John Lamberton.

Artists of earth and sky. Rawhide, bear claw, eagle feathers and the glory of America’s Plans Indians, on display at the Metropolitan Museum of Art.

 
Apr 24, 2015
The Rev. Jamal Bryant leads a rally outside of the Baltimore Police Department's Western District police station during a march and vigil for Freddie Gray, Tuesday, April 21, 2015, in Baltimore. (AP)

Loretta Lynch gets a vote. Race and anger in Baltimore. Migrant crisis in the Mediterranean. Petraeus, sentenced. Our weekly news roundtable goes behind the headlines.

On Point Blog
On Point Blog
Your Favorite Musical Memories Of Rain
Wednesday, Apr 22, 2015

When we say ‘rain,’ you say ‘…?’ (Here’s what you really said when we said ‘rain.’)

More »
6 Comments
 
Three LIVE Tracks From Flor De Toloache
Friday, Apr 17, 2015

Fantastic live tracks from the amazing women of Flor de Toloache.

More »
1 Comment
 
Our Week In The Web: April 17, 2015
Friday, Apr 17, 2015

Interactions on Facebook, campaign time begins and a truck full of bees.

More »
2 Comments